St. Judes Trifecta valve nets CE mark
St. Jude Medical has received CE mark approval for the Trifecta valve, marking the company’s launch into the market for pericardial aortic stented tissue valves.
The tri-leaflets are manufactured from pericardial tissue attached to the exterior of the valve stent, which open to perform like a natural heart valve, according to the St. Paul, Minn.-based company.
To provide support within the heart, the valve uses a titanium stent, which is covered with pericardial tissue to allow tissue-to-tissue contact when the leaflets open and close. This design reduces the amount of wear and deterioration, according to St. Jude.
The Trifecta also utilizes Linx, a patented anticalcification technology designed to reduce tissue hardening.
The tri-leaflets are manufactured from pericardial tissue attached to the exterior of the valve stent, which open to perform like a natural heart valve, according to the St. Paul, Minn.-based company.
To provide support within the heart, the valve uses a titanium stent, which is covered with pericardial tissue to allow tissue-to-tissue contact when the leaflets open and close. This design reduces the amount of wear and deterioration, according to St. Jude.
The Trifecta also utilizes Linx, a patented anticalcification technology designed to reduce tissue hardening.